Published in Hepatitis Weekly, December 18th, 2000
The patent, XTL's first for a specific antibody, covers human monoclonal antibodies (MAbs) directed against the hepatitis B virus (HBV) surface antigen (HbsAg). In addition, the patent covers pharmaceutical compositions for the treatment of HBV infection containing the antibodies. These antibodies can be given either as monotherapy or in combination with additional antiviral agents.
Mirit Lotan, PhD, XTL, stated, "XTL's...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.